NARIHIRO, S., SUWA, K., USHIGOME, T., OHTSU, M., RYU, S., SHIMOYAMA, Y., . . . YANAGA, K. (2018). Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer. In Vivo.
Stile di citazione ChicagoNARIHIRO, SATOSHI, KATSUHITO SUWA, TAKURO USHIGOME, MASAMICHI OHTSU, SYUNJIN RYU, YUYA SHIMOYAMA, TOMOYOSHI OKAMOTO, e KATSUHIKO YANAGA. "Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients With Unresectable Colorectal Cancer." In Vivo 2018.
Citazione MLANARIHIRO, SATOSHI, et al. "Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients With Unresectable Colorectal Cancer." In Vivo 2018.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.